CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. - Wikidata - awgldk - TriplyDB

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.

http://www.wikidata.org/entity/Q36551527

about

Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research The Global Alzheimer's Association Interactive Network Sharing data in the global alzheimer's association interactive network Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia TDP-43 suppresses tau expression via promoting its mRNA instability.Neurodegenerative disease: MRI biomarkers - a precision medicine tool in neurology?The power of neuroimaging biomarkers for screening frontotemporal dementia.The future of blood-based biomarkers for Alzheimer's disease.Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia.Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry The influence of cerebrospinal fluid (CSF) biomarkers on clinical dementia evaluations Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine.Homozygous carriers of APP A713T mutation in an autosomal dominant Alzheimer disease family The transitional association between β-amyloid pathology and regional brain atrophy Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings.An Assessment of Possible Neuropathology and Clinical Relationships in 46 Sporadic Amyotrophic Lateral Sclerosis Patient Autopsies Applied multimodal diagnostics in a case of presenile dementia.Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer's Disease Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study.Premotor biomarkers for Parkinson's disease - a promising direction of research.Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis.Multilevel Deficiency of White Matter Connectivity Networks in Alzheimer's Disease: A Diffusion MRI Study with DTI and HARDI Models Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology.Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease.Can MRI screen for CSF biomarkers in neurodegenerative disease?White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration

P2860

Q26864063-4275EC15-0C19-4A90-AA42-77FFEC746C50 Q27008249-6D939933-2FA4-4DCC-A8CF-2CE633DE47DC Q28088291-6DC8E22F-0587-40F7-9E44-AE8C98F92545 Q28601466-59133439-DC78-43A0-AE51-E80F6EA1077D Q28607247-D730611D-9DC2-4812-927A-1ECA157D2316 Q29620245-C59EAA40-A006-433D-9249-4EA5C0788509 Q30659251-7F91D03A-9981-4F5B-87EA-C7BC935192A9 Q31110973-708302B4-C1F2-4343-8583-CA90A8ED632A Q33554802-6980F096-725D-4055-ACF3-3D5722A62580 Q33559175-F84F76B4-3020-427F-8A13-694988C5B822 Q33666297-C328581B-6694-4D69-A653-6835AAA37FA2 Q33727909-4DE59DAE-05D6-4387-82AF-7CB4C9DC9E83 Q33740999-ACDBFECA-63CC-46D2-8001-8FB5B6A222CA Q33907524-2817790E-A47C-4E18-9D9C-60A50121DDB9 Q33934175-435AEAC2-6A47-4672-8419-5CD870EE6094 Q34026317-11DF3FA6-4CB3-40E9-81FD-1D60E61E0784 Q34079305-8186C52E-2A7F-4A7E-9F9C-71499136EFED Q34157882-1280F0F9-81A3-4C18-9568-CAD3E83B58E0 Q34873817-3B60721D-6706-4174-A116-68AFB81D1058 Q35204586-4420B7C3-9737-45EF-B8D5-67E706C41A32 Q35686163-08F9AA43-8B51-424E-9413-29FF1366882A Q35706871-D2E59419-B135-4254-98F1-982DAB9403F7 Q35889053-44455FC3-83A6-4A9D-BA42-404ACDD43C94 Q36030708-1892DFC5-8E3E-468E-88A9-1A35E3CA4F04 Q36099506-B41998D9-9D96-4DDF-BF0D-152DBDE3793D Q36157458-FF3822ED-E95E-4238-AD83-123EF488314C Q36271739-1BC44043-B8B7-472B-B079-872A946CBB9B Q36276506-7704A4EC-CA09-4455-9AC3-688EAC6CC363 Q36322982-0BB17D97-4C7E-4832-825C-36D41723D8E8 Q36353787-7F5DCBF2-3574-4650-B858-12DA7E5CCEA5 Q36444517-A31B96C3-F604-4017-9011-AB06812FFB6C Q36527483-377DA35B-6A8B-48EB-BA77-4FA47E9BCD30 Q36533528-D54D3438-5EEE-4534-B82D-56BF1D4B010D Q36581696-52ADAB39-9B65-4F4B-98FC-F1C95C5FB1E5 Q36626657-6130A1BB-8C43-48C5-90F9-541659CDD5F3 Q36659380-3310AE34-721B-4BA1-BF3B-8010AF14CF5E Q36874831-DEF190EC-4AAF-4F67-AA92-07E108B2494E Q36930623-3BC35195-E8C5-4BB1-9237-C8D2769D0AAF Q36998414-45096222-9D29-4610-9DCF-36BDFE815407 Q37079742-52E06456-EC6D-4752-9407-40E752104B8F

P2860

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.

http://www.wikidata.org/entity/Q36551527

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.

@ast

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.

@en

type

label

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.

@ast

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.

@en

prefLabel

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.

@ast

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.

@en

P1433

Q36551527-8AFB58D4-7D64-4EDD-9EF7-77EF483610D2

P1476

Q36551527-37452703-F898-4FA1-B94F-1CDD5EDA4E3E

P2093

Q36551527-318770B5-9C61-4C2C-8A2C-EFC2FE495C45

Q36551527-4C9CC614-E621-4814-BBE8-77C314180E59

Q36551527-9AC465DF-C5D8-4D7C-ABD4-DD809C90C4F8

Q36551527-9E8C96CE-5ACC-4376-BD81-A924894FAF33

Q36551527-B824995E-338A-4DFF-AEF1-39D6C982D128

Q36551527-E26471D2-5A8F-4C94-A255-F7BDEBE4417F

P2860

Q36551527-06D30FD3-7009-4573-BE6E-38BAB2A30D92

Q36551527-0AE85389-6B41-4F7D-B9A5-36779C3A0E8D

Q36551527-0F97B8E9-0289-477D-88D6-DAFB160BC5AF

Q36551527-106612F5-D2E3-4305-B471-503C347F81E8

Q36551527-18DFA5D9-9705-457A-9B21-D8C70B564DAD

Q36551527-20A9E9FD-86F9-4F12-ACA8-CCB4895F69A1

Q36551527-2209C041-B569-4BD5-A974-6CFD435DF61C

Q36551527-261E7980-7D76-49B8-B6CD-BCA56AC7F72B

Q36551527-277957C6-27A1-48E8-A8D9-7495D26E757D

Q36551527-2C5C76AF-F4E2-4D52-A916-ADEA7BC5132D

P2888

Q36551527-92FB6C44-0443-4F46-B9D8-174BD57B6A16

P304

Q36551527-A4C8361E-4927-446D-8F25-A60BDD89AB4B

P31

Q36551527-4AFBE1C0-4A19-4EA1-936D-49AA5DD7FBB3

P356

Q36551527-BB602798-843B-4D3B-AED0-ED796F321F1E

P433

Q36551527-4F40D8D9-3ABA-4F95-8E38-2EF3B0ABDE21

P478

Q36551527-898B369D-F313-4C5A-98B2-FCA0AFA066B3

P50

Q36551527-032BC4E4-540B-4D52-8AE4-F069C5B96549

Q36551527-4B6AD99C-F9FF-4CEF-9139-C03FFED029FE

Q36551527-6730D454-BD41-4A26-AD9B-B744E58D7E99

P577

Q36551527-471F2445-7090-4868-8FD9-78A4F7E9C100

P698

Q36551527-2CFF5428-4343-4631-9269-C10499D6AD0A

P921

Q36551527-6C823602-4008-4FAA-BACD-02D73F239CA5

P932

Q36551527-9C313103-C8D9-475D-A643-A92BF8D372E5

P356

S00401-012-0983-7

P1433

Acta Neuropathologica

P1476

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.

@en

P2093

Johannes Brettschneider

http://www.w3.org/2001/XMLSchema#string

Jon B Toledo

http://www.w3.org/2001/XMLSchema#string

Leslie M Shaw

http://www.w3.org/2001/XMLSchema#string

Sharon X Xie

http://www.w3.org/2001/XMLSchema#string

Virginia M-Y Lee

http://www.w3.org/2001/XMLSchema#string

William T Hu

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

Classification of primary progressive aphasia and its variants

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia

The clinical use of structural MRI in Alzheimer disease

Neuropathological stageing of Alzheimer-related changes

Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

P2888

s00401-012-0983-7

P304

23-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00401-012-0983-7

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

John Q. Trojanowski

Steven E. Arnold

Murray Grossman

P577

2012-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22526019

http://www.w3.org/2001/XMLSchema#string

P921

P932

3551449

http://www.w3.org/2001/XMLSchema#string